IL1B and chronic kidney disease: The fourth patient (pat 4) had already developed CKD G5DA3 already at the age of 24, followed by kidney transplantation three years later: With anti-IL-1 therapy he remained in CKD stage G2TA1 during 13 years of follow-up.